{"groups":[{"description":"LY2523355: Dose determined by participant's body surface area: 5 milligrams/square meter(mg/m²) or 6 mg/m², administered intravenously as a 1-hour infusion on Days 1, 2 and 3 of a 21-day cycle for up to 2 cycles (4 cycles for prostate cancer participants). Additional cycles administered based on participant response assessment.\n\nPegfilgrastim: 6 milligrams (mg), administered subcutaneously approximately 24 hours after third dose of LY2523355 on Day 4 of each 21-day cycle, for up to 2 cycles of LY2523355 administration (4 cycles for prostate cancer participants). Additional cycles of LY2523355 administered based on participant response assessment.","id":"FG000","title":"LY2523355"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Physician Decision"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"103"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"103"}],"type":"Received at Least 1 Dose of Study Drug"},{"achievements":[{"groupId":"FG000","numSubjects":"97"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"6"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"All participants who received at least one dose of study drug in both Cycle 1 and Cycle 2 or to have progressed or died on or before study Day 42 were considered to be completed."}